ZURICH (Thomson Financial) - Roche Holdings AG expects sales of its weight loss drug Xenical to go in Australia after a federal there banned direct advertising to consumers on concerns the drug was being sold to people who may not be it.'We have lost the ability to advertise using the brand label which makes it very difficult to promote so consumers will not ask for it by name in the pharmacies,' a Roche spokeswoman in Australia told Thomson Financial News. The pharmaceuticals assort is considering its options in the wake of the act's decision added the spokeswoman.'We feel we undergo done all we can and ordain now be considering the viability of supporting Xenical in the future,' said managing director of Roche Products Fred Nadjarian after the judgement was announced at the end of last month. Xenical is categorised as a Schedule 3 drug which means it is available without a prescription but consumers should acquire counselling as to its use sarah fenwick@thomson comsf/jmsCOPYRIGHTCopyright AFX News Limited 2007. All rights reserved. The copying republication or redistribution of AFX News Content including by framing or similar means is expressly prohibited without the prior written consent of AFX News.
You must log in to access this area of the place. If you are not a registered user to sign up for instant find!
*ABCMoney co uk does not guarantee the accuracy of any share prices or stock quotations displayed. These are not real time quotes; all are delayed by at least twenty minutes and are for information purposes only.[ADVERTHERE]Related article:
http://www.abcmoney.co.uk/news/052007129269.htm
comments | Add comment | Report as Spam
|
